Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Area of Science:

• Health economics
• Pharmaceutical policy
• Regulatory science

Background:

• Medicines Adaptive Pathways to Patients (MAPPs) is a regulatory initiative by the European Medicines Agency (EMA).
• MAPPs allows for conditional marketing authorization of medicines, potentially before comprehensive data is available.
• Payers were not involved in the initial introduction of MAPPs, leading to concerns.

Purpose of the Study:

• To outline the concept of MAPPs and identify associated challenges for payers.
• To discuss payer concerns and explore potential collaborative strategies.
• To provide recommendations for payers navigating MAPPs reimbursement.

Main Methods:

• Review of the MAPPs framework and its implications for market access.
• Analysis of payer activities including Health Technology Assessment (HTA), financial evaluation, and post-launch monitoring.
• Discussion of challenges related to clinical data immaturity, uncertainty, and pricing.

Main Results:

• MAPPs introduce significant challenges for payers, including HTA with uncertain data and complex negotiations.
• Payers express concerns regarding the potential shift of financial and side-effect burdens to the post-authorization phase.
• Reimbursement decisions for MAPPs medicines are expected to show greater variation compared to conventional approvals.

Conclusions:

• Payers require specific strategies to manage the uncertainties and financial risks associated with MAPPs-authorized medicines.
• Collaboration between stakeholders may be necessary to address the unique challenges posed by MAPPs.
• Further research and policy development are needed to ensure sustainable access to innovative medicines approved via adaptive pathways.